Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and raises the price target from $3 to $6.